Close
Improving clinical endpoints to help improve MND clinical trial outcomes

Improving clinical endpoints to help improve MND clinical trial outcomes

Reading Time: 5 minutes What is a clinical endpoint?

A clinical endpoint is used to determine if the drug that is being tested in a clinical trial is beneficial to the people it is intended to treat – those effects that directly measure how a participant in the trial feels, functions or survives.

To determine a clinical endpoint, it is important to understand how a person with a disease feels and functions, and this is well understood in MND. So, a drug that improves any of these could be seen to be beneficial.

Could evidence of MND be found years before the development of physical symptoms?

Could evidence of MND be found years before the development of physical symptoms?

Reading Time: 6 minutes A recent paper (October 2022), published in the journal Journal of Pathology: Clinical Research suggests that evidence of MND can be seen inside people years before they develop physical symptoms. The paper titled ‘pTDP-43 aggregates accumulate in non-central nervous system tissues prior to symptom onset in amyotrophic lateral sclerosis: a case series linking archival surgical biopsies…

A ‘wee molecule’: the tiny urinary biomarker neopterin and its role in MND progression

A ‘wee molecule’: the tiny urinary biomarker neopterin and its role in MND progression

Reading Time: 6 minutes My name is Stephanie Shepheard, and I am a Research Associate in the Motor Neuron Disease & Neurotrophic Research Laboratory (MND&NR Lab), Flinders Health & Medicine Research Institute in the College of Medicine & Public Health at Flinders University, South Australia. I measure biological changes, or biomarkers, that may tell us something useful about motor…

Symposium Spotlight: Biomarkers in MND – improving drug development and clinical trial design

Symposium Spotlight: Biomarkers in MND – improving drug development and clinical trial design

Reading Time: 4 minutes Diagnosing disease faster, accurately predicting disease progression, assessing the ability of a new drug to reach its target – I think we’d all agree that these three things are essential requirements for treating all diseases. But how can we achieve this? The answer may lie in biomarkers. In his plenary talk at last year’s International…